Endo grabs Aspen branded, generic meds; Ironwood, Actavis sponsor IBS survey;

> Endo International ($ENDP) snapped up a portfolio of branded and generic products from Aspen, expanding its presence in that company's home country of South Africa. Release

> Ironwood Pharmaceuticals and Actavis ($ACT) are sponsoring a broad survey of patients with irritable bowel syndrome, under the auspices of the American Gastroenterological Association. Release

> Spain's Almirall racked up €217 million in first-quarter sales, including a milestone payment from AstraZeneca ($AZN) stemming from a respiratory drug deal last year. Release

> Roche ($RHHBY) will roll out new pivotal data on its cancer drug Gazyva in non-Hodgkin's lymphoma and the as-yet-unapproved ALK inhibitor alectinib in non-small-cell lung cancer at the American Society for Clinical Oncology meeting later this month. Release

And Finally... The New Yorker returned to McAllen, TX, to find that the notoriously high-spending market has cut its health expenses substantially. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.